Dashboard
Manage Tickers

LAZLazard, Inc.

NYSE lazard.com


$ 37.86 $ 0.03 (0.08 %)    

Friday, 19-Apr-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 414.59 $ -8.76 (-2.07 %)
DIA $ 379.83 $ 1.96 (0.52 %)
SPY $ 494.96 $ -4.36 (-0.87 %)
TLT $ 89.15 $ 0.32 (0.36 %)
GLD $ 221.02 $ 0.69 (0.31 %)
$ 37.91
$ 38.03
$ 0.00 x 0
$ 0.00 x 0
$ 37.66 - $ 38.29
$ 34.38 - $ 42.24
463,382
na
3.37B
$ 1.34
nm
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-23-2024 12-31-2023 10-K
2 10-27-2023 09-30-2023 10-Q
3 07-31-2023 06-30-2023 10-Q
4 05-02-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 10-31-2022 09-30-2022 10-Q
7 08-01-2022 06-30-2022 10-Q
8 05-02-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-01-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-26-2021 12-31-2020 10-K
14 11-02-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-04-2020 03-31-2020 10-Q
17 02-25-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 07-29-2019 06-30-2019 10-Q
20 04-30-2019 03-31-2019 10-Q
21 02-26-2019 12-31-2018 10-K
22 10-29-2018 09-30-2018 10-Q
23 07-31-2018 06-30-2018 10-Q
24 04-30-2018 03-31-2018 10-Q
25 02-27-2018 12-31-2017 10-K
26 10-31-2017 09-30-2017 10-Q
27 08-01-2017 06-30-2017 10-Q
28 05-01-2017 03-31-2017 10-Q
29 02-24-2017 12-31-2016 10-K
30 10-28-2016 09-30-2016 10-Q
31 08-01-2016 06-30-2016 10-Q
32 04-27-2016 03-31-2016 10-Q
33 02-25-2016 12-31-2015 10-K
34 10-28-2015 09-30-2015 10-Q
35 07-27-2015 06-30-2015 10-Q
36 04-28-2015 03-31-2015 10-Q
37 02-27-2015 12-31-2014 10-K
38 10-28-2014 09-30-2014 10-Q
39 07-28-2014 06-30-2014 10-Q
40 05-06-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lazard-partners-with-elaia-to-launch-european-tech-investment-powerhouse
Lazard Partners With Elaia To Launch Europ...
04/18/2024 14:57:26

Lazard collaborates with Elaia Partners to establish Lazard Elaia Capital, aiming to become a prominent European tech investmen...

lazard-and-elaia-partners-ink-strategic-partnership-to-launch-lazard-elaia-capital-spearheading-tech-investments-in-europe
Lazard And Elaia Partners Ink Strategic Pa...
04/18/2024 07:07:35

analyst-ratings-for-lazard
Analyst Ratings For Lazard
04/11/2024 20:01:47

morgan-stanley-maintains-overweight-on-lazard-maintains-58-price-target
Morgan Stanley Maintains Overweight on Laz...
04/11/2024 14:16:59

Morgan Stanley analyst Ryan Kenny maintains Lazard (NYSE:LAZ) with a Overweight and maintains $58 price target.

lazard-reported-that-its-preliminary-assets-under-management-aum-as-of-march-31-2024-totaled-around-2504b
Lazard Reported That Its Preliminary Asset...
04/10/2024 10:51:42

decoding-5-analyst-evaluations-for-lazard
Decoding 5 Analyst Evaluations For Lazard
03/26/2024 19:01:56

ubs-maintains-neutral-on-lazard-raises-price-target-to-44
UBS Maintains Neutral on Lazard, Raises Pr...
03/26/2024 10:11:01

UBS analyst Brennan Hawken maintains Lazard (NYSE:LAZ) with a Neutral and raises the price target from $43 to $44.

lazard-reports-january-2024-assets-under-management-of-2438m-vs-2467m-in-december-2023
Lazard Reports January 2024 Assets Under M...
02/12/2024 11:48:35

Lazard, Inc. (NYSE: LAZ) reported today that its preliminary assets under management ("AUM") as of January 31, 2024 tot...

ubs-maintains-neutral-on-lazard-raises-price-target-to-43
UBS Maintains Neutral on Lazard, Raises Pr...
02/05/2024 18:45:46

UBS analyst Brennan Hawken maintains Lazard (NYSE:LAZ) with a Neutral and raises the price target from $40 to $43.

lazard-q4-adj-eps-066-beats-041-estimate-sales-76096m-beat-67717m-estimate
Lazard Q4 Adj EPS $0.66 Beats $0.41 Estima...
02/01/2024 11:46:43

Lazard (NYSE:LAZ) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.41 by 60.98 pe...

earnings-scheduled-for-february-1-2024
Earnings Scheduled For February 1, 2024
02/01/2024 10:03:12

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NY...

earnings-outlook-for-lazard
Earnings Outlook For Lazard
01/31/2024 17:01:24

4-analysts-have-this-to-say-about-lazard
4 Analysts Have This To Say About Lazard
01/29/2024 13:00:34

keefe-bruyette--woods-reinstates-outperform-on-lazard-announces-51-price-target
Keefe, Bruyette & Woods Reinstates Outperf...
01/29/2024 11:16:13

Keefe, Bruyette & Woods analyst Michael Brown reinstates Lazard (NYSE:LAZ) with a Outperform and announces $51 price tar...

Core News & Articles
LNG Developer Tellurian Hires Lazard To Ex...
01/25/2024 21:13:36

- Bloomberg

top-3-financial-stocks-that-may-implode-in-q1
Top 3 Financial Stocks That May Implode In Q1
01/19/2024 13:29:10

As of Jan. 19, 2024, three stocks in the financial sector could be flashing a real warning to investors who value momentum as a...

lazard-posted-preliminary-assets-under-management-aum-of-2467b-as-of-december-31-2023
Lazard Posted Preliminary Assets Under Man...
01/11/2024 11:56:39

expert-outlook-lazard-through-the-eyes-of-5-analysts
Expert Outlook: Lazard Through The Eyes Of...
01/09/2024 17:00:19

ubs-maintains-neutral-on-lazard-raises-price-target-to-40
UBS Maintains Neutral on Lazard, Raises Pr...
01/09/2024 15:51:00

UBS analyst Brennan Hawken maintains Lazard (NYSE:LAZ) with a Neutral and raises the price target from $31 to $40.

wolfe-research-upgrades-lazard-to-outperform-announces-42-price-target
Wolfe Research Upgrades Lazard to Outperfo...
01/03/2024 11:20:54

Wolfe Research analyst Steven Chubak upgrades Lazard (NYSE:LAZ) from Peer Perform to Outperform and announces $42 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)